The analysis of SEMA3F expression by IF revealed that on day 29 (IDC step) of the in vivo course, SEMA3F staining increased compared to that of the DCIS stage on day 7 (Fig. 1f, upper panel). Here, SEMA3F is linked to ductal breast carcinoma in situ.